Clinical study on Fuzheng Huayu Capsule combined with entecavir in treatment of chronic hepatitis B with liver fibrosis

Objective To investigate the effect of Fuzheng Huayu Capsule combined with entecavir in the treatment of chronic hepatitis B with liver fibrosis and its mechanism. Methods Collecting 112 cases suffered from chronic hepatitis B with liver fibrosis from May 2013 to November 2013 in the First People's Hospital of Xining, which were randomly divided into treatment group(56 cases) and control group(56 cases). Patients in the treatment group were po administered with Entecavir Tablets, 1 tablet each time, once daily. At the same time, they were po administered with Fuzheng Huayu Capsule, 1 grain each time, three times daily. Patients in the control group were po administered with Entecavir Tablets, and the usage and dosage were the same as the treatment group. And they were po administered with placebo, 1 grain each time, three times daily. Two groups were treated for 24 weeks. The symptoms, the degree of liver fibrosis and inflammation, liver function, the indexes of hepatic fibrosis and the expression of Fas in the two groups were compared. Results The improvement rates of fatigue, liver area pain, anorexia, abdominal distension in the treatment group were higher than those in the control group, with significant difference between the two groups(P 0.01). After the treatment, the degree of fibrosis, inflammation activity, and liver function in the two groups were significantly improved, and the difference was statistically significant before and after the treatment in the same group(P 0.01). And the degree of the improvement in the treatment group was better than that in the control group, with the significant difference between the two groups(P 0.05, 0.01). ALT and AST in the two groups were reduced, and the difference was statistically significant before and after the treatment in the same group(P 0.01). ALT in the treatment group was lower than that in the control group for treatment at 24 weeks, with significant difference between the two groups(P 0.05). After the treatment, the indexes of liver fibrosis, such as HA, LN, C-IV, PC Ⅲ, copy number of HBV DNA, and Fas expression were significantly reduced, and the difference was statistically significant before and after the treatment in the same group(P 0.01). And the patients in the treatment group improved more obviously than those in the control group in the same time of the treatment, with the significant difference between two groups(P 0.01). Conclusion Fuzheng Huayu Capsule combined with entecavir has good clinical effect in the treatment of chronic hepatitis B with liver fibrosis, and could better improve the symptom of the patients, at the same time, improve the degree of fibrosis and inflammation activity, which is worthy of clinical application.